We are pioneering Translation Control Therapeutics, a new class of drugs that specifically control protein translation
Translation Control Discovery Platform
With our technology we can visualize and specifically control the synthesis of target proteins, enabling a new strategy against many severe diseases
Translation Control Lab
Anima’s Translation Control Lab (TCL) is purpose-built for the discovery of translation modulators by integrating our proprietary technologies in biology, bioinformatics, big data image analysis and cloud software architecture
• Analysis Assessment
• Bio Data Analysis
Our pipeline programs are in Fibrosis (Collagen type I translation inhibitors), RSV (inhibiting the production of viral proteins by host cell ribosomes), Oncology (C-Myc translation inhibitors) and Huntington’s Disease (monitoring mutant Huntingtin translation pausing).
$30 million in upfront payments, $14 million in research funding, up to $1.05 billion in milestones and low to mid single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.
17 Scientific Collaborations
Eur J Cell Biol (2018) ; 97 : 168-179.
Integr Biol (2016); 8 :645-53
J Cell Biol. 2016; 23;213(4):451-62.
Nucleic Acid Res. (2017); 45 :926-937
News & Events
Anima Biotech announces an exclusive collaboration with Lilly for the discovery and development of translation inhibitors of several protein targets
When: July 23rd, 2018
Anima Biotech today announced an agreement with Lilly for the discovery and development of translation inhibitors for several target proteins by using Anima’s Translation Control Therapeutics platform.
International tRNA Conference 2018
When: September 23rd, 2018 - September 27th, 2018
Where: Strasbourg, France
Anima Biotech will participate and present at the 27th International tRNA Conference “tRNA at the crossroad”.
This event brings together researchers from around the world studying the many aspects of tRNA biology.
When: September 5th, 2018 - September 6th, 2018
Where: Boston, USA
Anima Biotech will participate and present at the 11th annual international partnering conference BIOPHARM AMERICA, part of BIOTECH WEEK BOSTON.
The conference is dedicated to building strategic partnerships with the brightest minds in biotech, pharma, and finance.